While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

The planned Shanghai facility extends a yearslong push into the field and will support CAR-T therapies AstraZeneca is making for autoimmune disease and cancer.

The clearance, issued 54 days after an approval submission, gives Novo another chance to claw back market share from Eli Lilly.

Retatrutide, a possible advance on GLP-1 drugs like Zepbound, significantly cut blood sugar and body weight in the study, a sign it might be similarly impactful against obesity.

After a lengthy downturn, renewed optimism is building among young drugmakers and their backers as a new funding wave takes shape, said Santé Ventures’ Omar Khalil.